Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | GRM8 | O00222 | 1/20 | 0.58 |
| ▸ | GRM6 | O15303 | 1/20 | 0.58 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.58 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.58 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.58 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.58 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.58 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.58 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.58 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.58 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.58 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL6668644 | 1.00 | GSR (0.58) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Arginine SCHEMBL577728 | 1.00 | GSR (0.58) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Arginine SCHEMBL6672058 | 1.00 | GSR (0.58) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Arginine SCHEMBL424415 | 1.00 | GSR (0.58) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Arginine SCHEMBL4749671 | 1.00 | GSR (0.58) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Arginine SCHEMBL6803653 | 1.00 | GSR (0.58) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Arginine SCHEMBL573880 | 1.00 | GSR (0.58) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Arginine SCHEMBL2582854 | 1.00 | GSR (0.58) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Arginine SCHEMBL578156 | 1.00 | GSR (0.58) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Arginine SCHEMBL3338199 | 0.98 | GSR (0.56) | GSRCYP1A2GRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9050365-B2 | Transdermal delivery of beneficial substances effected by a hostile biophysical environment | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2015-06-09 | — | — | US | claimed |
| US-20150080470-A1 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2015-03-19 | — | — | US | claimed |
| US-20150011570-A1 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2015-01-08 | — | — | US | claimed |
| US-20250241924-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4491225-A2 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | Strategic Science & Technologies, LLC (US) | 2025-01-15 | — | — | EP | disclosed |
| CN-119013028-A | Compositions and methods for ameliorating sexual dysfunction | 温桑托尔公司 | 2024-11-22 | — | — | CN | disclosed |
| US-12138268-B2 | Treatment of erectile dysfunction and other indications | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2024-11-12 | — | — | US | disclosed |
| CN-114668851-B | Treatment of erectile dysfunction and other indications | 战略科学与技术有限责任公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240358712-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SEXUAL SENSORY DISORDERS | WINSANTOR INC (US) | 2024-10-31 | — | — | US | disclosed |
| EP-3721893-B1 | TREATMENT OF ERECTILE DYSFUNCTION | STRATEGIC SCIENCE & TECH LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20230372351-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-1732577-A4 | TOPICAL DELIVERY OF A NITRIC OXIDE DONOR TO IMPROVE BODY AND SKIN APPEARANCE | STRATEGIC SCIENCE & TECHNOLOGI (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20080280984-A1 | Delivering drugs through skin such as analgesics, vitamins, peptides, dietary supplements, antiinflamamtory agents, antiulcer agents, removing fats and cellulite, anticancer agents | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080045909-A1 | Topical Delivery of a Nitric Oxide Donor to Improve and Skin Appearance | STRATEGIC SCIENCE & TECHNOLOGIES, LLC. (US) | 2008-02-21 | — | — | US | disclosed |
| EP-1737429-A1 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT | Strategic Science & Technologies, LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1737441-A2 | BENEFICIAL EFFECTS OF INCREASING LOCAL BLOOD FLOW | Strategic Science & Technologies, LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1732577-A2 | TOPICAL DELIVERY OF A NITRIC OXIDE DONOR TO IMPROVE BODY AND SKIN APPEARANCE | Strategic Science & Technologies, LLC (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005102282-A1 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005102307-A2 | BENEFICIAL EFFECTS OF INCREASING LOCAL BLOOD FLOW | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005081964-A2 | TOPICAL DELIVERY OF A NITRIC OXIDE DONOR TO IMPROVE BODY AND SKIN APPEARANCE | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12138268-B2 | Treatment of erectile dysfunction and other indications | PDE5A, PDE3A, PDE12 | GSR 358/4885CYP1A2 1183/4885GRM8 1334/4885 |
| US-20250241924-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | GSR 358/4885CYP1A2 1183/4885GRM8 1334/4885 |
| US-20230372351-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | GSR 358/4885CYP1A2 1183/4885GRM8 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.